MLH1 and lung carcinoma: hMLH1 promoter methylation [69] can lead to the occurrence of DDP resistance in vitro and in vivo, which can affect the therapeutic effect of patients, revealing that hMLH1 is capable of functioning as a biomarker for the individualized treatment of lung cancer.